No Data
Frontier Biotech: Frontier Biotech 2024 Annual Performance Report Announcement
Frontier Biotech 2024 Annual Results Report Announcement
Frontier Biotech (688221.SH): FB3002 Loxoprofen Sodium Patch has received the notification of acceptance for domestic pharmaceutical production registration and marketing license.
On January 20, Gelonghui reported that Frontier Bio (688221.SH) announced that its product under research, FB3002 (a hot melt adhesive patch for the treatment of musculoskeletal joint pain), has received a "Notice of Acceptance" for its generic drug marketing application issued by the National Medical Products Administration. FB3002, a high-end generic drug for the treatment of musculoskeletal joint pain, contains the active ingredient Loxoprofen Sodium, which is a non-steroidal anti-inflammatory pain reliever. Its mechanism of action is to inhibit the activity of cyclooxygenase, thereby suppressing the synthesis of prostaglandins, resulting in good analgesic and anti-inflammatory effects, especially in terms of pain relief.
Frontier Biotech 2024 Annual Performance Forecast
Qianyan Biology (688221.SH): Expected loss of 0.182 billion yuan to 0.22 billion yuan in 2024.
Gelonghui reported on January 17 that Frontier Bio (688221.SH) announced the annual performance forecast for 2024. According to preliminary estimates by the financial department, it is expected that the revenue for 2024 will be approximately 125 million to 130 million yuan, an increase of 9.41% to 13.79% year-on-year, mainly due to revenue growth from the anti-HIV Innovative Drugs product Aikenin and diversified business. According to preliminary estimates by the financial department, it is expected that the Net income attributable to shareholders of the listed company will show a loss of approximately 182 million to 220 million yuan, with a reduction in losses of about 10.
Is Frontier Biotechnologies (SHSE:688221) Weighed On By Its Debt Load?